144 related articles for article (PubMed ID: 12826646)
1. Hypereosinophilic syndrome.
Roufosse FE; Goldman M; Cogan E
N Engl J Med; 2003 Jun; 348(26):2687; author reply 2687. PubMed ID: 12826646
[No Abstract] [Full Text] [Related]
2. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
3. The hypereosinophilic syndrome and the biology of cancer.
Schwartz RS
N Engl J Med; 2003 Mar; 348(13):1199-200. PubMed ID: 12660383
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
[No Abstract] [Full Text] [Related]
5. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
Friedrich MJ
J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
[No Abstract] [Full Text] [Related]
6. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
7. The idiopathic hypereosinophilic syndrome and eosinophilic leukemias.
Bain B
Haematologica; 2004 Feb; 89(2):133-7. PubMed ID: 15003886
[No Abstract] [Full Text] [Related]
8. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
[TBL] [Abstract][Full Text] [Related]
9. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
[No Abstract] [Full Text] [Related]
10. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
11. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
12. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
13. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-KrzemieĊ S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
14. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
Koury MJ; Newman JH; Murray JJ
Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
[No Abstract] [Full Text] [Related]
15. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
Pardanani A; Reeder T; Porrata LF; Li CY; Tazelaar HD; Baxter EJ; Witzig TE; Cross NC; Tefferi A
Blood; 2003 May; 101(9):3391-7. PubMed ID: 12506022
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypereosinophilic syndrome with imatinib mesilate.
Gleich GJ; Leiferman KM; Pardanani A; Tefferi A; Butterfield JH
Lancet; 2002 May; 359(9317):1577-8. PubMed ID: 12047970
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
18. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.
Bain BJ
Br J Haematol; 2003 Jul; 122(2):173-9. PubMed ID: 12846884
[No Abstract] [Full Text] [Related]
20. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Onitilo AA; Kio EA; Singh AK; Lazarchick J
Leuk Lymphoma; 2005 Nov; 46(11):1667-70. PubMed ID: 16236620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]